BIWH-3 (Boehringer Ingelheim)-靶点: CCL2_适应症-临床_专利_批准
网页BIWH-3 (Boehringer Ingelheim)是由勃林格殷格翰研发的一种重组蛋白，是一种CCL2调节剂。 目前该药物最高研发阶段为终止，用于治疗外周动脉疾病。 BIWH-3 (Boehringer Ingelheim)-靶点: CCL2_适应症-临床_专利_批准
BIWH 3 in Peripheral Arterial Disease - ICH GCP
网页2014年8月12日 · The primary aim of this trial was to investigate the safety of a 6 hour intraarterial infusion of BIWH 3 (pyro-Glu-rhMCP-1) in patients with severe peripheral arterial occlusive disease (PAOD) and chronic Critical Limb Ischaemia (Fontaine class III or IV).
BIWH-3 (C.H. Boehringer Sohn AG & Co. KG)
网页BIWH-3(C.H. Boehringer Sohn AG & Co. KG): 一种CCL2调节剂药物，由C.H. Boehringer Sohn AG & Co. KG (C.H. Boehringer Sohn AG & Co. KG)公司最早进行研发，目前全球最高研发状态为终止，作用机制: CCL2调节剂(C-C基序趋化因子-2调节剂)，治疗领域: 心血管疾病。
PII‐60 - Hilbert - 2006 - Clinical Pharmacology & Therapeutics
网页BIWH 3 is a recombinant pyro-glu monocyte chemotactic protein-1 (MCP-1). Based on arteriogenic effects of MCP-1 in animals, MCP-1 was developed for critical limb ischemia. This study investigated safety, tolerability, and PK of BIWH 3 after single 1-hr iv infusions of 20 ng/kg −; 2 μg/kg in healthy males.
History of Changes for Study: NCT02215824
网页The primary aim of this trial was to investigate the safety of a 6 hour intraarterial infusion of BIWH 3 (pyro-Glu-rhMCP-1) in patients with severe peripheral arterial occlusive disease (PAOD) and chronic Critical Limb Ischaemia (Fontaine class III or IV).
BIWH-3(C.H. Boehringer Sohn AG & Co. KG) - Drug Targets, …
网页BIWH-3(C.H. Boehringer Sohn AG & Co. KG): a CCL2 modulators Drug, Initially developed by C.H. Boehringer Sohn AG & Co. KG, Now, its global highest R&D status is Discontinued, Mechanism: CCL2 modulators(C-C motif chemokine 2 modulators), Therapeutic Areas: Cardiovascular Diseases.
北京市危险化学品安全生产教育培训平台
网页2023年4月11日 · 本市首次制定危化品“禁限控”目录，246种危化品拟在京禁产. 2023-04-07 15:03:37.0.
PII-60Pharmacokinetics ABS pharmacodynamics of BIWH 3 in …
网页2006年2月1日 · Background/aims: BIWH 3 is a recombinant pyro-glu monocyte chemotactic protein-1 (MCP-1). Based on arteriogenic effects of MCP-1 in animals, MCP-1 was developed for critical limb ischemia. This...
PII-60Pharmacokinetics ABS pharmacodynamics of BIWH 3 in …
网页BACKGROUND/AIMS: BIWH 3 is a recombinant pyro-glu monocyte chemotactic protein-1 (MCP-1). Based on arteriogenic effects of MCP-1 in animals, MCP-1 was developed for critical limb ischemia. This study investigated safety, tolerability, and PK of BIWH 3 after single 1-hr iv infusions of 20 ng/kg - 2 g/kg in healthy males.
Trial | NCT02215824
网页The primary aim of this trial was to investigate the safety of a 6 hour intraarterial infusion of BIWH 3 (pyro-Glu-rhMCP-1) in patients with severe peripheral arterial occlusive disease (PAOD) and chronic Critical Limb Ischaemia (Fontaine class III or IV).